DERIVATIVES OF 3-[(1,2,3,4-TETRAHYDROISOQUINOLIN-2-YL)METHYL]-8-AZABICYCLO [3.2.1] OCTANE, THEIR PRODUCTION AND APPLICATION IN THERAPY

Compounds of general formula (I) in which each of R1, R2 and R3 represents a hydrogen or halogen atom or a hydroxy, alkyl or alkoxy group, R4 represents a hydrogen or halogen atom or an alkyl, 2-methoxyethoxy, alkoxy, cycloalkylmethoxy or phenylmethoxy group, or R3 and R4 together form a methylenedi...

Full description

Saved in:
Bibliographic Details
Main Authors MARABOUT BENOIT, SEVRIN MIREILLE, GEORGE PASCAL, MERLY JEAN-PIERRE
Format Patent
LanguageEnglish
Published 15.03.1999
Edition6
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Compounds of general formula (I) in which each of R1, R2 and R3 represents a hydrogen or halogen atom or a hydroxy, alkyl or alkoxy group, R4 represents a hydrogen or halogen atom or an alkyl, 2-methoxyethoxy, alkoxy, cycloalkylmethoxy or phenylmethoxy group, or R3 and R4 together form a methylenedioxy group, Z represents oxygen or two hydrogen atoms and R represents an ethoxy group when Z represents oxygen, or represents a phenyl group optionally substituted by one or more halogen atoms or alkyl, alkoxy or amino groups. The compounds have a strong affinity for dopamine receptors of D2 and D3 type and for serotonin receptors of 5-HT1A and 5-HT2 type and are mixed ligands. Other compounds have a strong affinity for the dopamine receptors of D3 type and a weak affinity for the dopamine receptors of D2 type and serotonin receptors of 5-HT1A and 5-HT2 and are therefore selective and specific ligands.
Bibliography:Application Number: PL19970329243